Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Nerlynx Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Nerlynx (neratinib) Prior Authorization

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and notification requirements for Nerlynx (neratinib) for members receiving treatment for breast cancer or cervical cancer. Members under age 19 process automatically without coverage review, while other members must meet the applicable clinical criteria.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyNerlynx (neratinib) Prior Authorization
    Policy CodePolicy N/A
    Change TypeAnnual review with material coverage updates
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable diagnosis, biomarker status, prior therapy, and treatment combination.
    SourceLink
    POLICY UPDATE CHANGES

    The brain metastases criteria were updated to recognize Nerlynx use with ado-trastuzumab emtansine, capecitabine, or paclitaxel for HER2-positive breast cancer with brain metastases.

    The clinical background and references were updated during the annual review.

    Coverage criteria include recurrent or metastatic HER2-positive cervical cancer treated with Nerlynx as second-line or subsequent therapy.

    Coverage criteria include extended adjuvant Nerlynx therapy for selected patients with node-positive, hormone receptor-positive, HER2-positive breast cancer at high risk of recurrence.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsStandard authorization period
    <19Automatic processing age
    3Brain metastases combination partners
    1, 2A, 2BAccepted NCCN categories
    No progressionReauthorization status

    Covered Indications and Authorization Requirements

    Patients Less Than 19 Years of Age

    Nerlynx will be approved when the member is less than 19 years of age.

    Patient is less than 19 years of age

    Authorization will be issued for 12 months.

    Early-Stage or Node-Positive Breast Cancer

    Nerlynx will be approved when at least ONE of the following pathways is met:

    ONE of the following

    • ALL of the following

      • Diagnosis of early-stage breast cancer
      • Disease is human epidermal growth factor receptor 2 (HER2)-positive
      • Used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy (e.g., Herceptin®, Kanjinti™)
    • ALL of the following

      • Diagnosis of node-positive breast cancer
      • Disease is hormone receptor (HR)-positive and HER2-positive
      • Used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy (e.g., Herceptin®, Kanjinti™)
      • Patient has a perceived high risk of recurrence

    Advanced or Metastatic Breast Cancer — Initial Authorization

    Nerlynx will be approved when at least ONE of the following pathways is met:

    ONE of the following

    • ALL of the following

      • Diagnosis of advanced or metastatic breast cancer
      • Disease is HER2-positive
      • Patient has received two or more prior anti-HER2-based regimens in the metastatic setting
      • Will be used in combination with capecitabine
    • ALL of the following

    Advanced or Metastatic Breast Cancer — Reauthorization

    Nerlynx will be approved when the following criterion is met:

    Patient does not show evidence of progressive disease while on Nerlynx therapy

    Authorization will be issued for 12 months.

    Breast Cancer with Brain Metastases — Initial Authorization

    Nerlynx will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of breast cancer
    • Patient has brain metastases
    • Disease is HER2-positive
    • ONE of the following medications used in combination with Nerlynx

      • Ado-trastuzumab emtansine
      • Capecitabine

    Breast Cancer with Brain Metastases — Reauthorization

    Nerlynx will be approved when the following criterion is met:

    Patient does not show evidence of progressive disease while on Nerlynx therapy

    Authorization will be issued for 12 months.

    Recurrent or Metastatic Cervical Cancer — Initial Authorization

    Nerlynx will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of recurrent or metastatic cervical cancer
    • Disease is HER2-positive
    • Used as second-line or subsequent therapy

    Cervical Cancer — Reauthorization

    Nerlynx will be approved when the following criterion is met:

    Patient does not show evidence of progressive disease while on Nerlynx therapy

    Authorization will be issued for 12 months.

    NCCN Recommended Regimens

    Nerlynx is covered when the drug has been recognized for treatment of the cancer indication by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium.

    The cancer indication is recognized by the NCCN Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

    Authorization and Documentation Actions

    Prior Authorization

    Age-Based Authorization Process

    For members younger than 19 years, Nerlynx processes automatically without a coverage review when the member meets the age criterion. Members aged 19 years or older require prior authorization under the applicable coverage criteria.

    • Members under age 19: authorization may be issued for 12 months.
    • Members age 19 or older: submit documentation for coverage review.
    Documentation Required

    Extended Adjuvant Breast Cancer Therapy

    Request authorization for extended adjuvant Nerlynx therapy when the applicable early-stage or node-positive breast cancer pathway is documented, including prior adjuvant trastuzumab-containing therapy.

    • Early-stage breast cancer that is HER2-positive and treated with extended adjuvant therapy following adjuvant trastuzumab-containing therapy, such as Herceptin or Kanjinti.

    Clinical Background

    Nerlynx (neratinib) is a kinase inhibitor used as a single agent for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. It is also used in combination with capecitabine for adults with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

    Clinical Terms and Biomarkers

    HER2-positive
    DefinitionHuman epidermal growth factor receptor 2 (HER2) status is a tumor biomarker used to determine eligibility for several Nerlynx pathways.
    Eligibility roleHER2-positive disease is required for early-stage, advanced or metastatic, and brain-metastatic breast cancer pathways, as well as recurrent or metastatic cervical cancer.
    Policy applicationThe policy requires documented HER2-positive disease for the applicable Nerlynx indication and treatment pathway.
    HR-positive
    DefinitionHormone receptor (HR)-positive status indicates that the disease is positive for hormone receptors.
    Policy applicationHR-positive disease is part of the node-positive breast cancer pathway when the disease is also HER2-positive and the patient has a perceived high risk of recurrence.

    Initial Authorization Pathways

    Early-stage or node-positive breast cancer

    Initial authorization requires one of the following pathways.

    • Early-stage pathway: Diagnosis of early-stage breast cancer; disease is HER2-positive; and Nerlynx is used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy
    • Node-positive pathway: Diagnosis of node-positive breast cancer; disease is HR-positive and HER2-positive; Nerlynx is used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy; and the patient has a perceived high risk of recurrence

    Advanced or metastatic breast cancer

    Initial authorization requires one of the following pathways.

    Reauthorization Requirements

    Breast cancer continuation

    Reauthorization is available when the patient does not show evidence of progressive disease while on Nerlynx therapy.

    No progression: Patient does not show evidence of progressive disease while on Nerlynx therapyNo progressive disease

    Authorization will be issued for 12 months.

    Cervical cancer continuation

    Reauthorization is available when the patient does not show evidence of progressive disease while on Nerlynx therapy.

    No progression: Patient does not show evidence of progressive disease while on Nerlynx therapyNo progressive disease

    Authorization will be issued for 12 months.

    Required Prior and Sequenced Therapy

    StepRequirementCoverage
    1Prior adjuvant trastuzumab-containing therapy, such as Herceptin or Kanjinti, is required for extended adjuvant breast cancer use.Required
    StepRequirementCoverage
    1At least two prior anti-HER2-based regimens in the metastatic setting are required before Nerlynx is used with capecitabine.Required
    StepRequirementCoverage
    1Prior CDK4/6 inhibitor therapy is required for the HR-positive/HER2-negative stage IV breast cancer pathway.Required
    StepRequirementCoverage
    2Nerlynx must be used as second-line or subsequent therapy for recurrent or metastatic HER2-positive cervical cancer.Required
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyNerlynx (neratinib) Prior Authorization
    Policy CodePolicy N/A
    Change TypeAnnual review with material coverage updates
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable diagnosis, biomarker status, prior therapy, and treatment combination.
    SourceLink
    On This Page
    Covered Indications and Authorization RequirementsAuthorization and Documentation ActionsClinical BackgroundClinical Terms and BiomarkersInitial Authorization PathwaysReauthorization RequirementsRequired Prior and Sequenced Therapy
    Diagnosis of stage IV (M1) breast cancer
  1. ONE of the following

    • BOTH of the following

      • Disease is hormone receptor (HR)-positive and HER2-negative
      • Patient has already received CDK4/6 inhibitor therapy
    • Disease is triple-negative
  2. Paclitaxel
  3. OR node-positive breast cancer that is HR-positive and HER2-positive, treated with extended adjuvant therapy following adjuvant trastuzumab-containing therapy, with perceived high risk of recurrence.
  4. Authorization is issued for 12 months; coverage is limited to 12 months per occurrence.
  5. Prior Authorization

    Advanced or Metastatic Breast Cancer

    For advanced or metastatic breast cancer, document the disease setting, HER2 status, prior anti-HER2 treatment, and required combination therapy, or document the applicable stage IV pathway.

    • Advanced or metastatic breast cancer that is HER2-positive, with two or more prior anti-HER2-based regimens in the metastatic setting, and Nerlynx used in combination with capecitabine.
    • OR stage IV (M1) breast cancer with HR-positive/HER2-negative disease after CDK4/6 inhibitor therapy, or triple-negative disease.
    • Initial authorization is issued for 12 months.
    Prior Authorization

    Breast Cancer With Brain Metastases

    For breast cancer with brain metastases, document the breast cancer diagnosis, brain metastases, HER2-positive status, and use of Nerlynx with one of the listed combination agents.

    • Required combination: ado-trastuzumab emtansine, capecitabine, or paclitaxel.
    • Initial authorization is issued for 12 months.
    Prior Authorization

    HER2-Positive Cervical Cancer

    For recurrent or metastatic cervical cancer, document HER2-positive disease and that Nerlynx will be used as second-line or subsequent therapy.

    • Initial authorization is issued for 12 months.

    Unsupported block type: documentation

    Documentation Required

    Prior Trastuzumab Therapy

    For extended adjuvant use, document prior adjuvant treatment containing trastuzumab, such as Herceptin or Kanjinti.

    • Prior trastuzumab-containing adjuvant therapy is required for the early-stage or node-positive breast cancer pathways.
    • Include the prior regimen in the clinical documentation.
    Documentation Required

    Prior Anti-HER2 Regimens

    For the advanced or metastatic HER2-positive breast cancer pathway, document that the member has received at least two prior anti-HER2-based regimens in the metastatic setting.

    • The two or more prior anti-HER2-based regimens must have been administered in the metastatic setting.
    • Nerlynx must be used in combination with capecitabine for this pathway.
    Documentation Required

    Prior CDK4/6 Inhibitor Therapy

    For the stage IV HR-positive/HER2-negative breast cancer pathway, document prior treatment with a CDK4/6 inhibitor.

    • The member must have stage IV (M1) breast cancer.
    • This pathway requires HR-positive, HER2-negative disease and prior CDK4/6 inhibitor therapy.
    Documentation Required

    Second-Line or Subsequent Cervical Cancer Therapy

    For recurrent or metastatic HER2-positive cervical cancer, document that Nerlynx is being prescribed as second-line or subsequent therapy.

    • The treatment line must be second-line or later.
    • The disease must be recurrent or metastatic and HER2-positive.
    • Authorization is issued for 12 months.
    Denial Risk

    Failure to Meet Indication or Continuation Criteria

    Coverage may be denied when the requested use does not satisfy the applicable indication, biomarker, prior-treatment, combination-therapy, or disease-status requirements. Reauthorization requires documentation that the patient does not show evidence of progressive disease while receiving Nerlynx.

    • Denial risk: diagnosis does not match an included early-stage, node-positive, advanced/metastatic, stage IV, brain-metastatic, or recurrent/metastatic cervical cancer indication.
    • Denial risk: required HER2, HR, or triple-negative biomarker status is not documented.
    • Denial risk: required prior trastuzumab, two or more prior metastatic anti-HER2 regimens, or prior CDK4/6 inhibitor therapy is not documented.
    • Denial risk: required combination therapy, including capecitabine or a listed brain-metastasis combination agent, is not documented.
    • Continuation may be denied when progressive disease is evident while on Nerlynx.
    Note

    Benefit and Regulatory Limitations

    Coverage is subject to the member-specific benefit plan, applicable federal and state requirements, and other policies or utilization-management programs. State mandates for off-label coverage or use of other compendium references may supersede language in the benefit document or notification criteria.

    • Verify member-specific benefit coverage before submission.
    • Apply applicable federal and state regulatory requirements.
    • Check for other policies and utilization-management requirements.
    Stage IV pathwayFor stage IV (M1) breast cancer, the policy recognizes HR-positive/HER2-negative disease when the patient has already received CDK4/6 inhibitor therapy.
    M1
    DefinitionM1 denotes stage IV breast cancer with distant metastatic disease.
    Policy applicationThe stage IV pathway requires a diagnosis of stage IV (M1) breast cancer.
    Eligible disease pathwaysStage IV disease must be either HR-positive/HER2-negative after CDK4/6 inhibitor therapy or triple-negative disease.
    HER2-positive metastatic pathway:
    Diagnosis of advanced or metastatic breast cancer; disease is HER2-positive; patient has received two or more prior anti-HER2-based regimens in the metastatic setting; and Nerlynx will be used in combination with capecitabine
    At least 2 prior metastatic anti-HER2 regimens
  6. Stage IV pathway

    • Disease subtype and prior therapy: Either HR-positive, HER2-negative disease with prior CDK4/6 inhibitor therapy, or triple-negative disease
  7. Breast cancer with brain metastases

    Initial authorization requires all listed criteria.

    Brain metastases: Diagnosis of breast cancer; patient has brain metastases; disease is HER2-positive; and Nerlynx is used in combination with one of the following: ado-trastuzumab emtansine, capecitabine, or paclitaxel

    Recurrent or metastatic cervical cancer

    Initial authorization requires all listed criteria.

    Cervical cancer: Diagnosis of recurrent or metastatic cervical cancer; disease is HER2-positive; and Nerlynx is used as second-line or subsequent therapySecond-line or subsequent therapy